Tempest Therapeutics (TPST) News Today $9.92 +0.07 (+0.71%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$10.32 +0.40 (+4.03%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TPST Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Tempest Therapeutics (NASDAQ:TPST) Shares Down 8.5% - What's Next?August 29 at 2:17 AM | americanbankingnews.comTempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | finanznachrichten.deTempest Therapeutics Advances Clinical Development with Orphan Drug Designations and Pivotal Trial Clearance for Amezalpat and TPST-1495August 11, 2025 | quiverquant.comQTempest Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 11, 2025 | globenewswire.comMorpheus-Liver Study: A New Horizon in Advanced Liver Cancer TreatmentAugust 4, 2025 | tipranks.comTempest Therapeutics’ Promising Advances in Liver Cancer TreatmentJuly 3, 2025 | tipranks.comTempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in China - NasdaqJuly 2, 2025 | nasdaq.comTempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in ChinaJune 30, 2025 | globenewswire.comTPST - Tempest Therapeutics Inc Valuation - MorningstarJune 27, 2025 | morningstar.comMTPST Tempest Therapeutics, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comTempest announces $4.6 million registered direct offering of common stock; shares decline over 13%June 11, 2025 | msn.comTempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common StockJune 11, 2025 | quiverquant.comQTempest Announces $4.6 Million Registered Direct Offering of Common StockJune 11, 2025 | globenewswire.comTempest Therapeutics Executives Sign Consulting Agreements, Company Explores Strategic AlternativesJune 7, 2025 | marketwatch.comTempest Therapeutics Shares Up, Executive Team Enters Into Consulting AgreementsJune 7, 2025 | marketwatch.comTempest Therapeutics stock rises on EMA Orphan Drug DesignationJune 5, 2025 | au.investing.comTempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCCJune 5, 2025 | globenewswire.comTempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 16, 2025 | finanznachrichten.deTempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | finance.yahoo.comTempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comTempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual MeetingApril 28, 2025 | globenewswire.comCash-strapped Bay Area biotech company lays off all but 5 employeesApril 24, 2025 | msn.comTempest Therapeutics: FDA Grants Orphan Drug Designation To TPST-1495April 23, 2025 | nasdaq.comTempest Therapeutics Receives FDA Orphan Drug Designation for TPST-1495 to Treat Familial Adenomatous PolyposisApril 23, 2025 | nasdaq.comTempest Therapeutics stock rises on FDA Orphan Drug DesignationApril 21, 2025 | in.investing.comTempest Therapeutics announces FDA granted ODD to TPST-1495April 21, 2025 | markets.businessinsider.comTempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAPApril 21, 2025 | globenewswire.comScotiabank Reiterates Sector Perform Rating for Tempest Therapeutics (NASDAQ:TPST)April 12, 2025 | marketbeat.comHC Wainwright Reiterates "Neutral" Rating for Tempest Therapeutics (NASDAQ:TPST)April 12, 2025 | marketbeat.comScotiabank Downgrades Tempest Therapeutics (TPST)April 11, 2025 | msn.comTempest Therapeutics downgraded to Sector Perform from Outperform at ScotiabankApril 10, 2025 | markets.businessinsider.comTempest Therapeutics downgraded to Neutral from Buy at H.C. WainwrightApril 10, 2025 | markets.businessinsider.comTempest hits funding block for Phase III liver cancer drug-in-waitingApril 10, 2025 | finance.yahoo.comTempest Therapeutics downgraded at Scotiabank as amezalpat finds no suitorsApril 10, 2025 | markets.businessinsider.comTempest Therapeutics to explore strategic alternativesApril 10, 2025 | markets.businessinsider.comTempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible MergerApril 10, 2025 | msn.comTempest Therapeutics Seeks Partner as It Explores Strategic AlternativesApril 9, 2025 | marketwatch.comTempest Therapeutics Terminates Loan Agreement with OxfordApril 9, 2025 | tipranks.comTempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder ValueApril 9, 2025 | globenewswire.comTempest Therpeutics trading halted, news pendingApril 9, 2025 | markets.businessinsider.comTempest Therapeutics price target lowered to $7 from $13 at ScotiabankMarch 28, 2025 | markets.businessinsider.comTempest Therapeutics price target lowered to $16 from $47 at H.C. WainwrightMarch 28, 2025 | markets.businessinsider.comTempest Therapeutics: Tempest Reports Year End 2024 Financial Results and Provides Business UpdateMarch 28, 2025 | finanznachrichten.deWilliam Blair Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)March 28, 2025 | markets.businessinsider.comTempest Reports Year End 2024 Financial Results and Provides Business UpdateMarch 27, 2025 | globenewswire.comTempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual MeetingMarch 25, 2025 | globenewswire.comTempest Therapeutics received ‘Study May Proceed’ letter from FDA on TPST-1495March 13, 2025 | markets.businessinsider.comFDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)March 13, 2025 | globenewswire.comTempest Therapeutics granted FTD from FDA for amezalpatFebruary 11, 2025 | markets.businessinsider.comTempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular CarcinomaFebruary 10, 2025 | globenewswire.com Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TPST Media Mentions By Week TPST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TPST News Sentiment▼1.311.05▲Average Medical News Sentiment TPST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TPST Articles This Week▼21▲TPST Articles Average Week Get the Latest News and Ratings for TPST and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Tempest Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies IMRX News NVCT News ACTU News CRBU News CYBN News MCRB News NKTX News KYTX News BDTX News GLSI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TPST) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
